Full-Time

Scientist 2

Radiochemistry, Preclinical

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

Compensation Overview

$65.3k - $121.3k/yr

Needham, MA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Data Analysis

Get referred to Perceptive

See people who can refer or advise you

Requirements
  • A Ph.D. in Chemistry or a relevant field with at least 3 years of experience, or a Master of Science degree with at least 5 years of experience, in an academic or pharmaceutical laboratory.
  • Experience working safely and compliantly with radioactive materials.
  • Ability to lift more than 40 pounds.
  • Proficiency with Microsoft Office.
  • Fluent English language skills.
  • Experience with small- and large-molecule radiochemistry labeling, purification, and formulation.
  • Working knowledge and experience with high-performance liquid chromatography and thin-layer chromatography techniques in radiochemistry.
  • Ability to collaborate across departments.
  • Ability to manage multiple projects and prioritize tasks effectively.
  • Strong written and verbal communication skills for audiences with varying levels of expertise.
Responsibilities
  • Execute and manage the production of radiotracers used in positron emission tomography and single-photon emission computed tomography imaging and therapeutic research studies.
  • Contribute to the design, development, and optimization of radiolabeled compounds targeting complex biological markers for positron emission tomography and single-photon emission computed tomography imaging and therapeutic studies.
  • Synthesize novel positron emission tomography, single-photon emission computed tomography, and therapeutic radiopharmaceuticals.
  • Develop purification methods for small and large molecules.
  • Develop analytical methods for high-performance liquid chromatography and thin-layer chromatography.
  • Develop release criteria for imaging studies.
  • Develop dose formulation processes.
  • Operate and maintain analytical and automated radiochemistry synthesis units.
  • Stay current on advancements in radiochemistry and imaging through literature review and attendance at scientific conferences.
  • Maintain clear, accurate, and up-to-date records.
  • Analyze data, recognize aberrant results, and propose corrective actions or next steps.
  • Summarize data for reports, papers, and presentations.
  • Manage multiple projects simultaneously and prioritize tasks effectively.
  • Mentor and guide junior team members.
  • Provide scientific expertise and troubleshoot internally and in communications with sponsors regarding radiochemistry.
Desired Qualifications
  • Experience with conjugation using chelators and labeling with radiometals.
  • Prior experience with fluorine-18 radiochemistry and radioiodination methods.

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Alpha-emitting oncology programs are expanding, and Perceptive targets this fast-growing niche.
  • The January 2026 $15M investment adds two-site At-211 infrastructure in the U.S. and U.K.
  • Exclusive MH3D service-provider status strengthens Perceptive's positioning with radiopharmaceutical sponsors.

What critics are saying

  • CapVest owns Perceptive after the 2025 Calyx acquisition, limiting strategic independence.
  • Ennov bought Calyx Enterprise Technology in February 2024, shrinking Perceptive's software breadth.
  • Perceptive now depends on radiopharmaceutical demand and MH3D execution for α-Sight™ adoption.

What makes Perceptive unique

  • Perceptive Discovery launched α-Sight™ with MH3D on April 15, 2026 for alpha imaging.
  • Perceptive invested $15M on January 8, 2026 to expand radiochemistry and At-211 capabilities.
  • Perceptive combines imaging, radiochemistry, VivoQuant™, and preclinical workflows across oncology and CNS.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.